Rational individualised selection of adjuvant therapy for ductal carcinoma in situ

The Lancet Oncology

Volumn 12, Issue 1, 2011, Pages 2-3

  Kuerer, Henry M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; BREAST RECONSTRUCTION; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; INTRADUCTAL CARCINOMA; LETTER; MASTECTOMY; PARTIAL BODY RADIATION; PRIORITY JOURNAL; RECURRENCE RISK;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 78650704196     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70277-1     Document Type: Letter

References (7)

1. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95-102.
2. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2010, published online Dec 8. 10.1016/S1470-2045(10)70266-7.
3. Pinder SE, Duggan C, Ellis IO, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 2010, 103:94-100.
4. Eng-Wong J, Costantino JP, Swain SM The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010, 2010:200-203.
5. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:5319-5324.
6. Silverstein MJ, Lagios MD Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr 2010, 2010:193-196.
7. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009, 27:279-288.